GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Cevimeline - EVOXAC oral capsules

Local official-label summaryBase record retrieved 2026-09-10See the evidence for this drug2 sources available - open source summaries, references and comparisons

EVOXAC / cevimeline

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Unstudied renal PK must not appear as no adjustment needed

The official and mirror sections agree on an evidence gap, not on an established CKD regimen.

Before applying: Keep renal and dialysis uncertainty visible, with stone and hydration precautions.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

EVOXAC - cevimeline hydrochloride capsules

Product / population
EVOXAC oral cevimeline capsules for dry-mouth symptoms in Sjogren syndrome; kidney-stone precautions and renal PK gaps are distinct.
Renal measure
Renal PK and dialyzability unestablished

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Renal dosing, restrictions and evidence limits

The official capsule label likewise leaves renal-impairment pharmacokinetics uninvestigated and dialyzability unknown. It cautions about nephrolithiasis-related renal colic/reflux and dehydration with excessive sweating.

Agreement with the mirror is agreement in these selected limitations, not validation of a dose for CKD or dialysis. Do not classify absence of a renal dosing instruction as a no-adjustment finding.

Source revision: Issued 02/2022; DailyMed updated 2022-09-07 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dac32a9b-05b8-42c2-9a29-d885a9279456

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

EVOXAC - cevimeline hydrochloride capsules

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

GlobalRPh RX List - EVOXAC

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

EVOXAC - cevimeline hydrochloride capsules

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Dialysis evidence: No dialysis regimen established in selected content

EVOXAC oral cevimeline capsules for dry-mouth symptoms in Sjogren syndrome; kidney-stone precautions and renal PK gaps are distinct.

Renal method: Renal PK and dialyzability unestablished
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - EVOXAC

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Dialysis evidence: No dialysis regimen established in selected content

EVOXAC oral cevimeline capsules for dry-mouth symptoms in Sjogren syndrome; kidney-stone precautions and renal PK gaps are distinct.

Renal method: Renal impairment not studied; no method or cutoff supplied
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Unstudied renal PK must not appear as no adjustment needed

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

absence of data not no adjustment

Unstudied renal PK must not appear as no adjustment needed

The official and mirror sections agree on an evidence gap, not on an established CKD regimen.

How to use this: Keep renal and dialysis uncertainty visible, with stone and hydration precautions.

GlobalRPh RX List - EVOXACEVOXAC - cevimeline hydrochloride capsules

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeEVOXAC - cevimeline hydrochloride capsulesGlobalRPh RX List - EVOXAC
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/evoxac-drug/

Exact product and population

EVOXAC oral cevimeline capsules for dry-mouth symptoms in Sjogren syndrome; kidney-stone precautions and renal PK gaps are distinct.

RDM58-SCOPE-cevimeline-evoxac · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

EVOXAC - cevimeline hydrochloride capsules

Open original reference

Open / share this exact local source

DailyMed / Cosette Pharmaceuticals, Inc. · EVOXAC oral cevimeline capsules for dry-mouth symptoms in Sjogren syndrome; kidney-stone precautions and renal PK gaps are distinct.

Renal method: Renal PK and dialyzability unestablished
Source date: Issued 02/2022; DailyMed updated 2022-09-07
Retrieved: 2026-09-10

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The official capsule label likewise leaves renal-impairment pharmacokinetics uninvestigated and dialyzability unknown. It cautions about nephrolithiasis-related renal colic/reflux and dehydration with excessive sweating.

Agreement with the mirror is agreement in these selected limitations, not validation of a dose for CKD or dialysis. Do not classify absence of a renal dosing instruction as a no-adjustment finding.

RDM58-official-cevimeline-evoxac-3f17019a75-C1 · Source locator: Clinical Pharmacology: Special Populations; Precautions; Management of Overdose

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dac32a9b-05b8-42c2-9a29-d885a9279456
Retrieved
2026-09-10
Exact label title
EVOXAC - cevimeline hydrochloride capsules
DailyMed Set ID
dac32a9b-05b8-42c2-9a29-d885a9279456
Labeler
Cosette Pharmaceuticals, Inc.
DailyMed page updated
2022-09-07
Label revision
Issued 02/2022; DailyMed updated 2022-09-07
FDA application
NDA020989
Renal-function method
Renal PK and dialyzability unestablished
Source date/version
Issued 02/2022; DailyMed updated 2022-09-07
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
9b9db40316add7979ba5b5f1212a3658206b0c32ec1de7b1d4b644c8b59ea1fb
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - EVOXAC

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · EVOXAC oral cevimeline capsules for dry-mouth symptoms in Sjogren syndrome; kidney-stone precautions and renal PK gaps are distinct.

Renal method: Renal impairment not studied; no method or cutoff supplied
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Renal-impairment effects on cevimeline pharmacokinetics have not been studied, and dialyzability is unknown. The selected source does not establish either a numeric renal adjustment or a no-adjustment recommendation.

Use cautiously with a history of nephrolithiasis because increased ureteral tone could precipitate renal colic or reflux. Monitor hydration when excessive sweating occurs; these precautions do not resolve the renal dosing evidence gap.

RDM58-rxlist-cevimeline-evoxac-6b174b8620-C1 · Source locator: Special Populations; Precautions: General; Overdose

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

A hosted label mirror is not independent corroboration of its underlying label. Official confirmation remains pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/evoxac-drug/
Retrieved
2026-09-10
Renal-function method
Renal impairment not studied; no method or cutoff supplied
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
e2312e9ae6e0427a60d767ca6ab58ca61b7c4abedf9a359b588b7f75155693df

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/evoxac-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
67bcc85055de42bb88893ea0b6b1d337df687db68269b5fd959455b04af6db52
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report